Sangamo price target lowered to $10 from $16 at Wedbush

Wedbush analyst Andreas Argyrides lowered the firm’s price target on Sangamo to $10 from $16 and keeps an Outperform rating on the shares. The company recently reported Q2 results and provided an update on the path to Phase 3 for ST-920/Fabray, with the Phase 3 protocol to be submitted to the FDA as early as YE23, the analyst tells investors in a research note.